Nothing out of the ordinary. Same as last year ex ofcourse the increase of authorized shares we voted on last year. I dont expect anything special from the upcoming ASM. I will however predict that the next ASM over 2023 will be a vote on a buyout bid for NWBO and NWBO will be a big pharma subsidiary as of after that.